People: Alder Biopharmaceuticals Inc (ALDR.OQ)
14 Jun 2019
Ms. Erin Lavelle is Chief Operating Officer of the Company. Ms. Lavelle has served as our Chief Operating Officer since April 2018. From October 2017 to March 2018, Ms. Lavelle served as the General Manager of the Taiwan affiliate of Amgen Inc., a biopharmaceutical company. From June 2016 to September 2017, Ms. Lavelle served as Executive Director, Japan and Asia-Pacific Commercial Excellence and Digital Health at Amgen. From July 2003 to June 2016, Ms. Lavelle served in roles of increasing responsibility at Amgen, including as Executive Director in the areas of Global Marketing; Global Commercial Finance; and Strategy and Corporate Development. She began her career in 1998 as an investment banker in the healthcare group at Merrill Lynch & Co. Ms. Lavelle holds a B.A. in Economics from Yale University.
|Total Annual Compensation, USD||283,590|
|Restricted Stock Award, USD||268,502|
|Long-Term Incentive Plans, USD||128,160|
|All Other, USD||3,000,140|
|Fiscal Year Total, USD||3,680,390|